Literature DB >> 17353634

[Recurrent esophageal cancer with complete response to TS-1 chemotherapy].

Takako Watanabe1, Takayuki Chinen, Norishige Nakachi, Manabu Nakamoto, Nobufumi Uchima, Tetsuo Hirata, Akira Hokama, Nagisa Kinjo, Fukunori Kinjo, Jiro Fujita.   

Abstract

An 80-year-old man was admitted to our hospital for treatment of recurrent esophageal cancer in December, 2004. He was diagnosed as having esophageal cancer of stage IVa (T2N4M0) in October, 2002, and he received chemoradiotherapy (nedaplatin (CDGP)/5-fluorouracil (5-FU) total 6 course+60 Gy). Afterwards, lymph nodes recurred, and two courses of CDGP/vindesine were given. Then, the primary lesion showed a complete response (CR), and lymph nodes a partial response (PR). In December, 2004, paraesophageal lymph nodes were enlarged to the size of 7 cm. On admission, because of renal disturbance and dementia with advanced age, we chose chemotherapy with TS-1 (100 mg/body/day, three weeks of administration, then two weeks of withdrawal). He had adverse effects of hematotoxicity of grade 3, and non-hematotoxicity of grade 1. He received 6 courses of this regimen and eventually showed CR. Serum SCC was decreased from 4.7 ng/mL to 0.9 ng/mL. At present,the lesions have not recurred during the follow-up for 18 months.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353634

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma.

Authors:  Ze-Tian Shen; Xin-Hu Wu; Bing Li; Jun-Shu Shen; Zhen Wang; Jing Li; Xi-Xu Zhu
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.